Remove 2001 Remove Communication Remove Drug Development
article thumbnail

Achieving scale up success under economic uncertainty

European Pharmaceutical Review

In 2001 and 2007, through 2009, the economy was hit hard. There was a significant slowdown in drug development, clinical trials, and new drugs coming to market. EMA prepares for winter antibiotic shortages That slowdown resulted in 211 drug shortages in 2010—the highest number recorded in a single year at the time.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

But what are the key potential changes and how could they impact drug developers and manufacturers? He noted that within the proposals, there is likely to be a differentiation in incentives for drug development in the orphan and unmet medical need areas. Key areas of potential legislative change. Future outlook.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Manufacturing the right talent

Express Pharma

With an aim to become more value-driven, India’s pharma industry is looking beyond generics, targeting innovations in drug development. Students here lack the basic English communication skills and require direction on career options,” highlighting the need to improve skilling in institutes at the tier-2 and tier-3 levels.

article thumbnail

The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development

Pharmaceutical Technology

As formulators, we are often able to directly impact the amount of drug absorbed through formulation optimization and improve exposure. However, the chances of improving the exposure profile of a drug that is highly cleared by formulation modification are limited. S54 – S61 (2001).

article thumbnail

Pathbreakers: The journey of first generics

Pharmaceutical Technology

from 2001 to 2022.” In 2017, FDA announced the Drug Competition Action Plan (DCAP) to allow consumers to get access to medicines. She says in those cases the FDA applies a multiple first-applicant approach to eligibility for 180-day exclusivity. However, that percentage of multiple first generics is not very high—approximately 10.6%

article thumbnail

Rare Disease Day: Why raising awareness is essential for a fairer future

Pharmaceutical Technology

Orphan drug development is expanding Change is happening. 1983 was a pivotal year for the rare disease community, with the US Food and Drug Administration’s introduction of the Orphan Drug Act. With similar incentives offered by EU/EEA and UK law, orphan drug development has taken off.

article thumbnail

Meet the company on a mission to transform research and advance healthcare

Pharmaceutical Technology

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development.